[Federal Register Volume 79, Number 221 (Monday, November 17, 2014)]
[Notices]
[Pages 68455-68456]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-27083]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Heterocyclic Compounds for the Treatment of Hepatitis C Virus
Description of Technology: The vast majority of people infected
with Hepatitis C Virus (HCV) will have chronic infection. Over decades,
this can lead to liver disease and liver cancer. In fact, HCV infection
is the leading cause of liver transplants in the U.S. Several new drugs
have recently come into the market that have changed the HCV treatment
paradigm. However, the effectiveness of these new drugs can vary
depending on the HCV genotype. Furthermore, all oral, interferon free
therapeutic regimens for HCV infection will need combinations of drugs
that target different aspects of the HCV life cycle. Thus, there is
still the need for additional new therapeutics against HCV.
The subject technologies are aryloxazole based small molecules that
are potent inhibitors of HCV infection and replication. The compounds
exhibit synergy with currently available therapeutics for HCV and
represent a new class of anti-HCV compounds. The compounds affect the
entry step of HCV infection, a step not targeted by currently available
therapeutics against HCV.
Potential Commercial Applications: Prevention and treatment of HCV
infection.
Competitive Advantages:
Potent inhibitors of HCV infection and replication.
Show synergistic effect with currently available HCV
therapeutics.
Represent new class of HCV inhibitors that target the
entry step of HCV infection.
Development Stage:
Early-stage.
In vitro data available.
[[Page 68456]]
Inventors: Jake Tsanyang Liang (NIDDK), Zongyi Hu (NIDDK), Juan
Jose Marugan (NCATS), Noel Terrance Southhall (NCATS), Xin Hu (NCATS),
Jingbo Xiao (NCATS), Shanshan He (NIDDK), Marc Ferrer-Alegre (NCATS),
Wei Zhang (NCATS)
Intellectual Property: HHS Reference No. E-161-2014/0--U.S.
Provisional Patent Application No. 62/011,462 filed 12 June2014
Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018;
[email protected]
Autodock Vina Software Process for Efficient Large-Scale Cognate Ligand
Screening
Description of Technology: The invention pertains to software
processes, additions, and docking approaches to Autodock Vina that
speeds the rate and efficiency of analyzing ligand interactions with a
receptor by cognate ligands and rewards conformations in the scoring
algorithm for residue interactions that are based on the biological
data. The score is multiplied by a weighting factor to control the
degree of ligand-residue interactions that are considered. This
multiplier is then added to the docking score for confirmation. This
new scoring mechanism is used to score each compound in each generation
of the evolutionary genetic algorithm. This docking approach can be
used to score and rank compounds in large-scale virtual screening
applications. The software includes logic for converting SDF formatted
to an Autodock Vina compatible format (containing approx. 25,000
compounds each) and submits the job to the portable batch system on the
computing cluster to convert into PDBC files (a concatenated filed
type). Modified Vina software stores the analyzed binding pocket in RAM
that does not have to be recomputed upon every docking process. This
increases the efficiency of the docking algorithm by several orders of
magnitude. The software on the head node intelligently monitors memory
usage, CPU usage and docking speed. Based on this information, the head
node elastically controls the load on each node.
Potential Commercial Applications:
Drug screening.
Ligand identification.
Competitive Advantages:
Speed.
Batch processing.
Efficient CPU processing.
Development Stage: In vitro data available.
Inventors: Marvin Gershengorn, Umesh Padia, Janak Padia, Elizabeth
Geras-Raaka (all of NIDDK).
Intellectual Property: HHS Reference No. E-289-2014/0--Software
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019;
[email protected].
Collaborative Research Opportunity: The National Institutes of
Diabetes and Digestive and Kidney Diseases is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Cognate Ligand
Identification. For collaboration opportunities, please contact Anna
Amar at 301-451-2305 or [email protected].
Dated: November 10, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-27083 Filed 11-14-14; 8:45 am]
BILLING CODE 4140-01-P